The innate and adaptive immunological aspects in neurodegenerative diseases

Journal of Neuroimmunology

Volumn 269, Issue 1-2, 2014, Pages 1-8

  Rodrigues, Maria C O ^a   Sanberg, Paul R ^b   Cruz, Luis Eduardo ^c   Garbuzova Davis, Svitlana ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Cryopraxis   (Brazil)

Author keywords

Adaptive immunity; Alzheimer's disease; Amyotrophic lateral sclerosis; Innate immunity; Neurodegenerative diseases; Parkinson's disease

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; FRACTALKINE;

ADAPTIVE IMMUNITY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CELL ACTIVATION; COMPLEMENT ACTIVATION; DEGENERATIVE DISEASE; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION;

ADAPTIVE IMMUNITY; ALZHEIMER'S DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; INNATE IMMUNITY; NEURODEGENERATIVE DISEASES; PARKINSON'S DISEASE;

ADAPTIVE IMMUNITY; ANIMALS; HUMANS; IMMUNITY, INNATE; NEURODEGENERATIVE DISEASES;

EID: 84896389377     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2013.09.020     Document Type: Review

References (144)

1. Alexianu M.E., Mohamed A.H., Smith R.G., Colom L.V., Appel S.H. Apoptotic cell death of a hybrid motoneuron cell line induced by immunoglobulins from patients with amyotrophic lateral sclerosis. J. Neurochem. 1994, 63:2365-2368.
2. Alexianu M.E., Kozovska M., Appel S.H. Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology 2001, 57:1282-1289.
3. Appel S.H., Stewart S.S., Appel V., Harati Y., Mietlowski W., Weiss W., Belendiuk G.W. A double-blind study of the effectiveness of cyclosporine in amyotrophic lateral sclerosis. Arch. Neurol. 1988, 45:381-386.
4. Appel S.H., Beers D.R., Henkel J.S. T cell-microglial dialogue in Parkinson's disease and amyotrophic lateral sclerosis: are we listening?. Trends Immunol. 2010, 31:7-17.
5. Arroyo D.S., Soria J.A., Gaviglio E.A., Rodriguez-Galan M.C., Iribarren P. Toll-like receptors are key players in neurodegeneration. Int. Immunopharmacol. 2011, 11:1415-1421.
6. Banerjee R., Mosley R.L., Reynolds A.D., Dhar A., Jackson-Lewis V., Gordon P.H., Przedborski S., Gendelman H.E. Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS ONE 2008, 3:e2740.
7. Barnett M.H., Parratt J.D.E., Cho E.-S., Prineas J.W. Immunoglobulins and complement in postmortem multiple sclerosis tissue. Ann. Neurol. 2009, 65:32-46.
8. Bartos A., Fialová L., Svarcová J., Ripova D. Patients with Alzheimer disease have elevated intrathecal synthesis of antibodies against tau protein and heavy neurofilament. J. Neuroimmunol. 2012, 252:100-105.
9. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 1995, 38:357-366.
10. Beal M.F. Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis. Ann. Neurol. 1998, 44:S110-114.
11. Beers D.R., Henkel J.S., Zhao W., Wang J., Appel S.H. CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:15558-15563.
12. Beers D.R., Henkel J.S., Zhao W., Wang J., Huang A., Wen S., Liao B., Appel S.H. Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 2011, 134:1293-1314.
13. Beers D.R., Zhao W., Liao B., Kano O., Wang Jinghong, Huang A., Appel Stanley H., Henkel J.S. Neuroinflammation modulates distinct regional and temporal clinical responses in ALS mice. Brain Behav. Immun. 2011, 25:1025-1035.
14. Benner E.J., Banerjee R., Reynolds A.D., Sherman S., Pisarev V.M., Tsiperson V., Nemachek C., Ciborowski P., Przedborski S., Mosley R.L., Gendelman H.E. Nitrated alpha-synuclein immunity accelerates degeneration of nigral dopaminergic neurons. PLoS ONE 2008, 3:e1376.
15. Bhaskar K., Konerth M., Kokiko-Cochran O.N., Cardona A., Ransohoff R.M., Lamb B.T. Regulation of tau pathology by the microglial fractalkine receptor. Neuron 2010, 68:19-31.
16. Boillée S., Yamanaka K., Lobsiger C.S., Copeland N.G., Jenkins N.A., Kassiotis G., Kollias G., Cleveland D.W. Onset and progression in inherited ALS determined by motor neurons and microglia. Science 2006, 312:1389-1392.
17. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci. Lett. 1994, 172:151-154.
18. Bouras C., Riederer B.M., Kövari E., Hof P.R., Giannakopoulos P. Humoral immunity in brain aging and Alzheimer's disease. Brain Res. Brain Res. Rev. 2005, 48:477-487.
19. Breitner J.C., Baker L.D., Montine T.J., Meinert C.L., Lyketsos C.G., Ashe K.H., Brandt J., Craft S., Evans D.E., Green R.C., Ismail M.S., Martin B.K., Mullan M.J., Sabbagh M., Tariot P.N. Extended results of the Alzheimer's disease anti-inflammatory prevention trial. Alzheimers Dement. 2011, 7:402-411.
20. Brochard V., Combadière B., Prigent A., Laouar Y., Perrin A., Beray-Berthat V., Bonduelle O., Alvarez-Fischer D., Callebert J., Launay J.-M., Duyckaerts C., Flavell R.A., Hirsch E.C., Hunot S. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009, 119:182-192.
21. Cardona A.E., Pioro E.P., Sasse M.E., Kostenko V., Cardona S.M., Dijkstra I.M., Huang D., Kidd G., Dombrowski S., Dutta R., Lee J.-C., Cook D.N., Jung S., Lira S.A., Littman D.R., Ransohoff R.M. Control of microglial neurotoxicity by the fractalkine receptor. Nat. Neurosci. 2006, 9:917-924.
22. Carson M.J., Bilousova T.V., Puntambekar S.S., Melchior B., Doose J.M., Ethell I.M. A rose by any other name? The potential consequences of microglial heterogeneity during CNS health and disease. Neurotherapeutics 2007, 4:571-579.
23. Castaño A., Herrera A.J., Cano J., Machado A. Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system. J. Neurochem. 1998, 70:1584-1592.
24. Chen K., Huang J., Gong W., Iribarren P., Dunlop N.M., Wang J.M. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 2007, 7:1271-1285.
25. Chiò A., Mora G., La Bella V., Caponnetto C., Mancardi G., Sabatelli M., Siciliano G., Silani V., Corbo M., Moglia C., Calvo A., Mutani R., Rutella S., Gualandi F., Melazzini M., Scimè R., Petrini M., Bondesan P., Garbelli S., Mantovani S., Bendotti C., Tarella C. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: clinical and biological results from a prospective multicenter study. Muscle Nerve 2011, 43:189-195.
26. Chiu I.M., Chen A., Zheng Y., Kosaras B., Tsiftsoglou S.A., Vartanian T.K., Brown R.H., Carroll M.C. T lymphocytes potentiate endogenous neuroprotective inflammation in a mouse model of ALS. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:17913-17918.
27. Cho S.-H., Sun B., Zhou Y., Kauppinen T.M., Halabisky B., Wes P., Ransohoff R.M., Gan L. CX3CR1 protein signaling modulates microglial activation and protects against plaque-independent cognitive deficits in a mouse model of Alzheimer disease. J. Biol. Chem. 2011, 286:32713-32722.
28. Colton C.A., Mott R.T., Sharpe H., Xu Q., Van Nostrand W.E., Vitek M.P. Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J. Neuroinflammation 2006, 3:27.
29. Consilvio C., Vincent A.M., Feldman E.L. Neuroinflammation, COX-2, and ALS-a dual role?. Exp. Neurol. 2004, 187:1-10.
30. Corrada M.M., Berlau D.J., Kawas C.H. A population-based clinicopathological study in the oldest-old: the 90+ study. Curr. Alzheimer Res. 2012, 9:709-717.
31. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
32. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:8850-8855.
33. Deng H.-X., Chen W., Hong S.-T., Boycott K.M., Gorrie G.H., Siddique N., Yang Y., Fecto F., Shi Y., Zhai H., Jiang H., Hirano M., Rampersaud E., Jansen G.H., Donkervoort S., Bigio E.H., Brooks B.R., Ajroud K., Sufit R.L., Haines J.L., Mugnaini E., Pericak-Vance M.A., Siddique T. Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia. Nature 2011, 477:211-215.
34. Depboylu C., Schorlemmer K., Klietz M., Oertel W.H., Weihe E., Höglinger G.U., Schäfer M.K.-H. Upregulation of microglial C1q expression has no effects on nigrostriatal dopaminergic injury in the MPTP mouse model of Parkinson disease. J. Neuroimmunol. 2011, 236:39-46.
35. Desideri G., Cipollone F., Necozione S., Marini C., Lechiara M.C., Taglieri G., Zuliani G., Fellin R., Mezzetti A., di Orio F., Ferri C. Enhanced soluble CD40 ligand and Alzheimer's disease: evidence of a possible pathogenetic role. Neurobiol. Aging 2008, 29:348-356.
36. Drachman D.B., Chaudhry V., Cornblath D., Kuncl R.W., Pestronk A., Clawson L., Mellits E.D., Quaskey S., Quinn T., Calkins A. Trial of immunosuppression in amyotrophic lateral sclerosis using total lymphoid irradiation. Ann. Neurol. 1994, 35:142-150.
37. Drachman Daniel B., Frank K., Dykes-Hoberg M., Teismann P., Almer G., Przedborski S., Rothstein J.D. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol. 2002, 52:771-778.
38. Duan R.-S., Yang X., Chen Z.-G., Lu M.-O., Morris C., Winblad B., Zhu J. Decreased fractalkine and increased IP-10 expression in aged brain of APP(swe) transgenic mice. Neurochem. Res. 2008, 33:1085-1089.
39. Engelhardt J.I., Soós J., Obál I., Vigh L., Siklós L. Subcellular localization of IgG from the sera of ALS patients in the nervous system. Acta Neurol. Scand. 2005, 112:126-133.
40. Farkas I., Takahashi M., Fukuda A., Yamamoto N., Akatsu H., Baranyi L., Tateyama H., Yamamoto T., Okada N., Okada H. Complement C5a receptor-mediated signaling may be involved in neurodegeneration in Alzheimer's disease. J. Immunol. 2003, 170:5764-5771.
41. Ferraiuolo L., Heath P.R., Holden H., Kasher P., Kirby J., Shaw P.J. Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS. J. Neurosci. 2007, 27:9201-9219.
42. Fialová L., Svarcová J., Bartos A., Ridzon P., Malbohan I., Keller O., Rusina R. Cerebrospinal fluid and serum antibodies against neurofilaments in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2010, 17:562-566.
43. Gagne J.J., Power M.C. Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 2010, 74:995-1002.
44. Gao H.-M., Kotzbauer P.T., Uryu K., Leight S., Trojanowski J.Q., Lee V.M.-Y. Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J. Neurosci. 2008, 28:7687-7698.
45. Glass C.K., Saijo K., Winner B., Marchetto M.C., Gage F.H. Mechanisms underlying inflammation in neurodegeneration. Cell 2010, 140:918-934.
46. Goldknopf I.L., Sheta E.A., Bryson J., Folsom B., Wilson C., Duty J., Yen A.A., Appel S.H. Complement C3c and related protein biomarkers in amyotrophic lateral sclerosis and Parkinson's disease. Biochem. Biophys. Res. Commun. 2006, 342:1034-1039.
47. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., Tandan R. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 2007, 6:1045-1053.
48. Gourie-Devi M., Nalini A., Subbakrishna D.K. Temporary amelioration of symptoms with intravenous cyclophosphamide in amyotrophic lateral sclerosis. J. Neurol. Sci. 1997, 150:167-172.
49. Greiner A., Schmausser B., Petzold K., Krüger H., Marx A. Neuronal targets of serum and cerebrospinal fluid autoantibodies in amyotrophic lateral sclerosis. Acta Neuropathol. 1996, 91:67-71.
50. Griffin W.S., Stanley L.C., Ling C., White L., MacLeod V., Perrot L.J., White C.L., Araoz C. Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1989, 86:7611-7615.
51. Hall E.D., Oostveen J.A., Gurney M.E. Relationship of microglial and astrocytic activation to disease onset and progression in a transgenic model of familial ALS. Glia 1998, 23:249-256.
52. Hanisch U.-K. Microglia as a source and target of cytokines. Glia 2002, 40:140-155.
53. Hanisch U.-K., Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 2007, 10:1387-1394.
54. Heese K., Hock C., Otten U. Inflammatory signals induce neurotrophin expression in human microglial cells. J. Neurochem. 1998, 70:699-707.
55. Henkel J.S., Beers D.R., Zhao W., Appel S.H. Microglia in ALS: the good, the bad, and the resting. J. Neuroimmune Pharmacol. 2009, 4:389-398.
56. Henkel J.S., Beers D.R., Wen S., Rivera A.L., Toennis K.M., Appel J.E., Zhao W., Moore D.H., Powell S.Z., Appel S.H. Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival. EMBO Mol. Med. 2013, 5:64-79.
57. Huang X., Reynolds A.D., Mosley R.L., Gendelman H.E. CD 4+ T cells in the pathobiology of neurodegenerative disorders. J. Neuroimmunol. 2009, 211:3-15.
58. Huppa J.B., Davis M.M. T-cell-antigen recognition and the immunological synapse. Nat. Rev. Immunol. 2003, 3:973-983.
59. Ilieva H., Polymenidou M., Cleveland D.W. Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J. Cell Biol. 2009, 187:761-772.
60. Karlsson J., Fong K.S.K., Hansson M.J., Elmér E., Csiszar K., Keep M.F. Life span extension and reduced neuronal death after weekly intraventricular cyclosporin injections in the G93A transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosurg. 2004, 101:128-137.
61. Kawai T., Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010, 11:373-384.
62. Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am. J. Pathol. 1992, 140:691-707.
63. Keep M., Elmér E., Fong K.S., Csiszar K. Intrathecal cyclosporin prolongs survival of late-stage ALS mice. Brain Res. 2001, 894:327-331.
64. Keller A.F., Gravel M., Kriz J. Treatment with minocycline after disease onset alters astrocyte reactivity and increases microgliosis in SOD1 mutant mice. Exp. Neurol. 2011, 228:69-79.
65. Khandelwal P.J., Herman A.M., Moussa C.E.-H. Inflammation in the early stages of neurodegenerative pathology. J. Neuroimmunol. 2011, 238:1-11.
66. Kriz J., Nguyen M.D., Julien J.-P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002, 10:268-278.
67. Kuzmenok O.I., Sanberg P.R., Desjarlais T.G., Bennett S.P., Garbuzova-Davis S.N. Lymphopenia and spontaneous autorosette formation in SOD1 mouse model of ALS. J. Neuroimmunol. 2006, 172:132-136.
68. Larbi A., Pawelec G., Witkowski J.M., Schipper H.M., Derhovanessian E., Goldeck D., Fulop T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. J. Alzheimers Dis. 2009, 17:91-103.
69. Lee S., Varvel N.H., Konerth M.E., Xu Guixiang, Cardona A.E., Ransohoff R.M., Lamb B.T. CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. Am. J. Pathol. 2010, 177:2549-2562.
70. Loeffler D.A., Juneau P.L., Nguyen H.U., Najman D., Pomara N., LeWitt P.A. Immunocytochemical detection of anti-hippocampal antibodies in Alzheimer's disease and normal cerebrospinal fluid. Neurochem. Res. 1997, 22:209-214.
71. Lombardi V.R., García M., Rey L., Cacabelos R. Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's disease (AD) individuals. J. Neuroimmunol. 1999, 97:163-171.
72. Lopez O.L., Rabin B.S., Huff F.J. Serum auto-antibodies in Alzheimer's disease. Acta Neurol. Scand. 1991, 84:441-444.
73. Lucin K.M., Wyss-Coray T. Immune activation in brain aging and neurodegeneration: too much or too little?. Neuron 2009, 64:110-122.
74. Maier M., Peng Y., Jiang L., Seabrook T.J., Carroll M.C., Lemere C.A. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J. Neurosci. 2008, 28:6333-6341.
75. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004, 25:677-686.
76. McCoy M.K., Martinez T.N., Ruhn K.A., Szymkowski D.E., Smith C.G., Botterman B.R., Tansey K.E., Tansey M.G. Blocking soluble tumor necrosis factor signaling with dominant-negative tumor necrosis factor inhibitor attenuates loss of dopaminergic neurons in models of Parkinson's disease. J. Neurosci. 2006, 26:9365-9375.
77. McGeer P.L., McGeer E.G. Inflammatory processes in amyotrophic lateral sclerosis. Muscle Nerve 2002, 26:459-470.
78. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1291.
79. McNaught K.S.P., Olanow C.W. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann. Neurol. 2003, 53(Suppl. 3):S73-84. (discussion S84-86).
80. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449:819-826.
81. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., Budson A.E., Sperling R., Selkoe D.J., Weiner H.L. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 2003, 112:415-422.
82. Mosley R.L., Hutter-Saunders J.A., Stone D.K., Gendelman H.E. Inflammation and adaptive immunity in Parkinson's disease. Cold Spring Harb. Perspect. Med. 2012, 2:a009381.
83. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
84. Mount M.P., Lira A., Grimes D., Smith P.D., Faucher S., Slack R., Anisman H., Hayley S., Park D.S. Involvement of interferon-gamma in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 2007, 27:3328-3337.
85. Nagatsu T., Mogi M., Ichinose H., Togari A. Cytokines in Parkinson's disease. J. Neural Transm. Suppl. 2000, 143-151.
86. Naor S., Keren Z., Bronshtein T., Goren E., Machluf M., Melamed D. Development of ALS-like disease in SOD-1 mice deficient of B lymphocytes. J. Neurol. 2009, 256:1228-1235.
87. Nefussy B., Artamonov I., Deutsch V., Naparstek E., Nagler A., Drory V.E. Recombinant human granulocyte-colony stimulating factor administration for treating amyotrophic lateral sclerosis: a pilot study. Amyotroph. Lateral Scler. 2010, 11:187-193.
88. Niebroj-Dobosz I., Jamrozik Z., Janik P., Hausmanowa-Petrusewicz I., Kwiecinski H. Anti-neural antibodies in serum and cerebrospinal fluid of amyotrophic lateral sclerosis (ALS) patients. Acta Neurol. Scand. 1999, 100:238-243.
89. Niebroj-Dobosz I., Dziewulska D., Janik Piotr Auto-antibodies against proteins of spinal cord cells in cerebrospinal fluid of patients with amyotrophic lateral sclerosis (ALS). Folia Neuropathol. 2006, 44:191-196.
90. Nikolaev A., McLaughlin T., O'Leary D.D.M., Tessier-Lavigne M. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
91. Orr H.T., Zoghbi H.Y. Reversing neurodegeneration: a promise unfolds. Cell 2000, 101:1-4.
92. Park D.R., Thomsen A.R., Frevert C.W., Pham U., Skerrett S.J., Kiener P.A., Liles W.C. Fas (CD95) induces proinflammatory cytokine responses by human monocytes and monocyte-derived macrophages. J. Immunol. 2003, 170:6209-6216.
93. Peterson L.J., Flood P.M. Oxidative stress and microglial cells in Parkinson's disease. Mediators Inflamm. 2012, 2012:401264.
94. Pitzer C., Krüger C., Plaas C., Kirsch F., Dittgen T., Müller R., Laage R., Kastner S., Suess S., Spoelgen R., Henriques A., Ehrenreich H., Schäbitz W.-R., Bach A., Schneider A. Granulocyte-colony stimulating factor improves outcome in a mouse model of amyotrophic lateral sclerosis. Brain 2008, 131:3335-3347.
95. Pollari E., Savchenko E., Jaronen M., Kanninen K., Malm T., Wojciechowski S., Ahtoniemi T., Goldsteins G., Giniatullina R., Giniatullin R., Koistinaho J., Magga J. Granulocyte colony stimulating factor attenuates inflammation in a mouse model of amyotrophic lateral sclerosis. J. Neuroinflammation 2011, 8:74.
96. Povova J., Ambroz P., Bar M., Pavukova V., Sery O., Tomaskova H., Janout V. Epidemiological of and risk factors for Alzheimer's disease: a review. Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2012, 156:108-114.
97. Prinz M., Priller J., Sisodia S.S., Ransohoff R.M. Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat. Neurosci. 2011, 14:1227-1235.
98. Provinciali L., Laurenzi M.A., Vesprini L., Giovagnoli A.R., Bartocci C., Montroni M., Bagnarelli P., Clementi M., Varaldo P.E. Immunity assessment in the early stages of amyotrophic lateral sclerosis: a study of virus antibodies and lymphocyte subsets. Acta Neurol. Scand. 1988, 78:449-454.
99. Pullen A.H., Demestre M., Howard R.S., Orrell R.W. Passive transfer of purified IgG from patients with amyotrophic lateral sclerosis to mice results in degeneration of motor neurons accompanied by Ca2+ enhancement. Acta Neuropathol. 2004, 107:35-46.
100. Qiu C., Kivipelto M., von Strauss E. Epidemiology of Alzheimer's disease: occurrence, determinants, and strategies toward intervention. Dialogues Clin. Neurosci. 2009, 11:111-128.
101. Rapp S.R., Espeland M.A., Shumaker S.A., Henderson V.W., Brunner R.L., Manson J.E., Gass M.L.S., Stefanick M.L., Lane D.S., Hays J., Johnson K.C., Coker L.H., Dailey M., Bowen D. Effect of estrogen plus progestin on global cognitive function in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 2003, 289:2663-2672.
102. Reynolds A.D., Banerjee R., Liu J., Gendelman H.E., Mosley R.L. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 2007, 82:1083-1094.
103. Reynolds A.D., Stone D.K., Mosley R.L., Gendelman H.E. Proteomic studies of nitrated alpha-synuclein microglia regulation by CD4+CD25+ T cells. J. Proteome Res. 2009, 8:3497-3511.
104. Reynolds A.D., Stone D.K., Hutter J.A.L., Benner E.J., Mosley R.L., Gendelman H.E. Regulatory T cells attenuate Th17 cell-mediated nigrostriatal dopaminergic neurodegeneration in a model of Parkinson's disease. J. Immunol. 2010, 184:2261-2271.
105. Richard K.L., Filali M., Préfontaine P., Rivest S. Toll-like receptor 2 acts as a natural innate immune receptor to clear amyloid beta 1-42 and delay the cognitive decline in a mouse model of Alzheimer's disease. J. Neurosci. 2008, 28:5784-5793.
106. Richartz E., Noda S., Schott K., Günthner A., Lewczuk P., Bartels M. Increased serum levels of CD95 in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2002, 13:178-182.
107. Riederer I.M., Pfulg C., Bouras C., Giannakopoulos P., Riederer B.M. Human immunoglobulins and Fc fragments promote microtubule assembly via tau proteins and induce conformational changes of neuronal microtubules in vitro. Neuroreport 2003, 14:117-121.
108. Roodveldt C., Christodoulou J., Dobson C.M. Immunological features of alpha-synuclein in Parkinson's disease. J. Cell. Mol. Med. 2008, 12:1820-1829.
109. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59-62.
110. Saleh I.A., Zesiewicz T., Xie Y., Sullivan K.L., Miller A.M., Kuzmin-Nichols N., Sanberg P.R., Garbuzova-Davis S. Evaluation of humoral immune response in adaptive immunity in ALS patients during disease progression. J. Neuroimmunol. 2009, 215:96-101.
111. Sanchez-Guajardo V., Febbraro F., Kirik D., Romero-Ramos M. Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS ONE 2010, 5:e8784.
112. Sano M., Bell K.L., Galasko D., Galvin J.E., Thomas R.G., van Dyck C.H., Aisen P.S. A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 2011, 77:556-563.
113. Schiffer D., Fiano V. Astrogliosis in ALS: possible interpretations according to pathogenetic hypotheses. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2004, 5:22-25.
114. Schindowski K., Leutner S., Müller W.E., Eckert A. Age-related changes of apoptotic cell death in human lymphocytes. Neurobiol. Aging 2000, 21:661-670.
115. Scholtzova H., Kascsak R.J., Bates K.A., Boutajangout A., Kerr D.J., Meeker H.C., Mehta P.D., Spinner D.S., Wisniewski T. Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J. Neurosci. 2009, 29:1846-1854.
116. Seksenyan A., Ron-Harel N., Azoulay D., Cahalon L., Cardon M., Rogeri P., Ko M.K., Weil M., Bulvik S., Rechavi G., Amariglio N., Konen E., Koronyo-Hamaoui M., Somech R., Schwartz M. Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis. J. Cell. Mol. Med. 2010, 14:2470-2482.
117. Shan S., Hong-Min T., Yi F., Jun-Peng G., Yue F., Yan-Hong T., Yun-Ke Y., Wen-Wei L., Xiang-Yu W., Jun M., Guo-Hua W., Ya-Ling H., Hua-Wei L., Ding-Fang C. New evidences for fractalkine/CX3CL1 involved in substantia nigral microglial activation and behavioral changes in a rat model of Parkinson's disease. Neurobiol. Aging 2011, 32:443-458.
118. Sherman M.Y., Goldberg A.L. Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases. Neuron 2001, 29:15-32.
119. Sierra A., Abiega O., Shahraz A., Neumann H. Janus-faced microglia: beneficial and detrimental consequences of microglial phagocytosis. Front. Cell. Neurosci. 2013, 7:6.
120. Small G.W., Rosenthal M., Tourtellotte W.W. Central nervous system IgG synthesis rates in Alzheimer disease: possible differences in early-onset and late-onset subgroups. Alzheimer Dis. Assoc. Disord. 1994, 8:29-37.
121. Solito E., Sastre M. Microglia function in Alzheimer's disease. Front. Pharmacol. 2012, 3:14.
122. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997, 388:839-840.
123. Streit W.J. Microglia as neuroprotective, immunocompetent cells of the CNS. Glia 2002, 40:133-139.
124. Sulger J., Dumais-Huber C., Zerfass R., Henn F.A., Aldenhoff J.B. The calcium response of human T lymphocytes is decreased in aging but increased in Alzheimer's dementia. Biol. Psychiatry 1999, 45:737-742.
125. Tada S., Okuno T., Yasui T., Nakatsuji Y., Sugimoto T., Kikutani H., Sakoda S. Deleterious effects of lymphocytes at the early stage of neurodegeneration in an animal model of amyotrophic lateral sclerosis. J. Neuroinflammation 2011, 8:19.
126. Tahara K., Kim H.-D., Jin J.-J., Maxwell J.A., Li L., Fukuchi K. Role of toll-like receptor signalling in Abeta uptake and clearance. Brain 2006, 129:3006-3019.
127. Tan J., Town T., Paris D., Mori T., Suo Z., Crawford F., Mattson M.P., Flavell R.A., Mullan M. Microglial activation resulting from CD40-CD40L interaction after beta-amyloid stimulation. Science 1999, 286:2352-2355.
128. Tan J., Town T., Crawford F., Mori T., DelleDonne A., Crescentini R., Obregon D., Flavell R.A., Mullan M.J. Role of CD40 ligand in amyloidosis in transgenic Alzheimer's mice. Nat. Neurosci. 2002, 5:1288-1293.
129. Todd Roach J., Volmar C.-H., Dwivedi S., Town T., Crescentini R., Crawford F., Tan J., Mullan M. Behavioral effects of CD40-CD40L pathway disruption in aged PSAPP mice. Brain Res. 2004, 1015:161-168.
130. Togo T., Akiyama H., Kondo H., Ikeda K., Kato M., Iseki E., Kosaka K. Expression of CD40 in the brain of Alzheimer's disease and other neurological diseases. Brain Res. 2000, 885:117-121.
131. Togo T., Akiyama H., Iseki E., Kondo H., Ikeda K., Kato M., Oda T., Tsuchiya K., Kosaka K. Occurrence of T cells in the brain of Alzheimer's disease and other neurological diseases. J. Neuroimmunol. 2002, 124:83-92.
132. Touil T., Fitzgerald D., Zhang G.-X., Rostami A., Gran B. Cutting edge: TLR3 stimulation suppresses experimental autoimmune encephalomyelitis by inducing endogenous IFN-beta. J. Immunol. 2006, 177:7505-7509.
133. Turner M.R., Cagnin A., Turkheimer F.E., Miller C.C.J., Shaw C.E., Brooks D.J., Leigh P.N., Banati R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis. 2004, 15:601-609.
134. Van Kooten C., Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 2000, 67:2-17.
135. Walker L.C., LeVine H. The cerebral proteopathies: neurodegenerative disorders of protein conformation and assembly. Mol. Neurobiol. 2000, 21:83-95.
136. Wang J., Xu G., Slunt H.H., Gonzales V., Coonfield M., Fromholt D., Copeland N.G., Jenkins N.A., Borchelt D.R. Coincident thresholds of mutant protein for paralytic disease and protein aggregation caused by restrictively expressed superoxide dismutase cDNA. Neurobiol. Dis. 2005, 20:943-952.
137. Webster S., Lue L.F., Brachova L., Tenner A.J., McGeer P.L., Terai K., Walker D.G., Bradt B., Cooper N.R., Rogers J. Molecular and cellular characterization of the membrane attack complex, C5b-9, in Alzheimer's disease. Neurobiol. Aging 1997, 18:415-421.
138. Weydt P., Möller T. The role of microglial cells in amyotrophic lateral sclerosis. Phys. Med. Rehabil. Clin. N. Am. 2005, 16:1081-1090. (xi).
139. Woodruff T.M., Crane J.W., Proctor L.M., Buller K.M., Shek A.B., de Vos K., Pollitt S., Williams H.M., Shiels I.A., Monk P.N., Taylor S.M. Therapeutic activity of C5a receptor antagonists in a rat model of neurodegeneration. FASEB J. 2006, 20:1407-1417.
140. Woodruff T.M., Costantini K.J., Crane J.W., Atkin J.D., Monk P.N., Taylor Stephen M., Noakes P.G. The complement factor C5a contributes to pathology in a rat model of amyotrophic lateral sclerosis. J. Immunol. 2008, 181:8727-8734.
141. Woodruff T.M., Costantini K.J., Taylor S.M., Noakes P.G. Role of complement in motor neuron disease: animal models and therapeutic potential of complement inhibitors. Adv. Exp. Med. Biol. 2008, 632:143-158.
142. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.-K., Ischiropoulos H., Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 2002, 22:1763-1771.
143. Wu D.C., Tieu K., Cohen O., Choi D.-K., Vila M., Jackson-Lewis V., Teismann P., Przedborski S. Glial cell response: a pathogenic factor in Parkinson's disease. J. Neurovirol. 2002, 8:551-558.
144. Wyss-Coray T., Loike J.D., Brionne T.C., Lu E., Anankov R., Yan F., Silverstein S.C., Husemann J. Adult mouse astrocytes degrade amyloid-beta in vitro and in situ. Nat. Med. 2003, 9:453-457.